In breast cancer, miR-194 also acts as an epi-miRNA by targeting DNMT3A [59], while miR-194-3p controls the expression of the DNA methylation reader MeCP2 [60], allowing the recruitment of DNTMs and histone deacetylases [61]. Here, DNMT3A is linked to breast cancer.